Welcome to the UPF Digital Repository

Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain

Show simple item record

dc.contributor.author Bura, S. Andreea, 1978-
dc.contributor.author Guegan, Thomas, 1983-
dc.contributor.author Zamamillo Castanedo, Daniel
dc.contributor.author Vela, José M.
dc.contributor.author Maldonado, Rafael, 1961-
dc.date.accessioned 2015-03-27T08:00:59Z
dc.date.available 2015-03-27T08:00:59Z
dc.date.issued 2013
dc.identifier.citation Bura SA, Guegan T, Zamanillo D, Vela JM, Maldonado R. Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain. Eur J Pain. 2013 Jul;17(6):832-43. DOI: 10.1002/j.1532-2149.2012.00251.x
dc.identifier.issn 1090-3801
dc.identifier.uri http://hdl.handle.net/10230/23299
dc.description.abstract BACKGROUND: The treatment of neuropathic pain is unsatisfactory at the present moment and the sigma 1 receptor has been identified as a new potential target for neuropathic pain. The aim of this study was to use an operant self-administration model to reveal the potential interest of a new sigma 1 receptor antagonist, S1RA, in chronic pain that was developed in mice by a partial ligation of the sciatic nerve. METHODS: Once that chronic pain had reached a steady state, mice were trained to maintain an operant behaviour to self-administer S1RA. The possible abuse liability of the analgesic compound was determined by evaluating operant self-administration in sham-operated mice. The influence of S1RA on the anhedonic state related to chronic pain was also evaluated by measuring the preference for palatable drink (2% sucrose solution) using a recently validated and highly sensitive behavioural device. RESULTS: Nerve-injured mice, but not sham-operated animals, acquired the operant responding to obtain S1RA (6 mg/kg/infusion). After 10 days of S1RA self-administration, neuropathic pain was significantly reduced in nerve-injured mice. In addition, an anhedonic state was revealed in nerve-injured mice by a decreased consumption of palatable drink, which was significantly attenuated by S1RA (25 mg/kg). CONCLUSIONS: These results reveal the analgesic efficacy of the sigma antagonist, S1RA, in neuropathic pain associated with an improvement of the emotional negative state and that was devoided of reinforcing effects. The operant responses evaluated in this new mouse model can have a high predictive value to estimate the clinical benefit/risk ratio of new analgesic compounds to treat chronic pain, such as S1RA.
dc.description.sponsorship S1RA was provided by Esteve as a gift within research projects funded by the CENIT program (CEN-20061005) from the Centro para el Desarollo Technológico Industrial from the Spanish Ministry of Science and Innovation (#SAF2007-64062), “Redes temáticas de investigación cooperativa en salud (RETICS) del Instituto de Salud Carlos III (RD06/001/001). Red de trastornos adictivos (RTA)”, the Catalan Government (SGR2009-00131), the ICREA Foundation (ICREA Academia-2008) and the DG Research of the European Commission (PHECOMP, #LSHM-CT-2007-037669)
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley-Blackwell
dc.relation.ispartof European Journal of Pain. 2013 Jul;17(6):832-43
dc.rights © Wiley-Blackwell. The definitive version is available at www3.interscience.wiley.com
dc.subject.other Analgèsics -- Ús terapèutic
dc.subject.other Neuràlgia
dc.title Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1002/j.1532-2149.2012.00251.x
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP6/37669
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PN/SAF2007-64062
dc.rights.accessRights info:eu-repo/semantics/openAccess

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking